Proactive Investors - Run By Investors For Investors

Breakfast News - Triple Point Social Housing REIT; Genedrive

Breakfast News - Triple Point Social Housing REIT; Genedrive

Small Cap Breakfast

Set menu


Total number of AIM Companies (Incl Susp):


Total number of AIM Companies trading:


*as at close of business  12 July 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):


Total number of Standard List Companies trading:


*as at close of business 12 July 2018

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):


Total number of NEX Growth Market Companies trading:


*as at close of business  12 July 2018

*A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

Dish of the day

ASA International (LON:ASAI) Main Mkt Prem— “one of the world's largest and most profitable international microfinance institutions, which aims to enhance financial inclusion among low-income populations throughout Asia and Africa in a socially responsible manner”.
Secondary sell down—40m shares at 313p.  Mkt  Cap £313m.  The company has issued $299m (£226m) of gross loans since 2013 with an average 25 per cent return on average equity over that period. Its profit last year was $29m.

Off the menu  

No Leavers Today

What’s cooking in the IPO kitchen?

NEX Exchange Growth Market

Veni Vidi Vici. Investment Vehicle to identify investment opportunities and acquisitions in companies in the Precious Metals and Base Metals sectors.  Raising £490k at 50p. Market cap £0.8m. Due 8 August.


Trackwise—established business that manufactures specialist products using printed circuit technology. Offer TBA. Due Late July

Ovoca Gold (to be renamed Ovoca Bio PLC) - RTO of IVIX, a Russian company developing a drug candidate for the treatment of female sexual dysfunctions. No monies to be raised, market cap of £8.5m, due 30 July

Nucleus Financial—independent wrap platform provider . FYDec17 revs £40.36m and PBT of £5.1m. Offer TBA. Due late July.

Kropz PLC-Intention to float by the  emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa and exploration assets in West Africa

Main Market (Standard)

Okyo Pharma—Formerly West African minerals. Delisted from AIM  earlier in year. Involved in the appraisal of opportunities in the life sciences and biotechnology sector. Moving from AIM to standard. Involved in two projects, one in ocular heath, and the other in non-opioid pain relief.

Danakali—potash company focused on the development of the Colluli Potash Project in Eritrea. Currently on ASX, Mkt cap c.£108m.

Breakfast Buffet

International Personal Finance (LON:IPF) 212p £444m

“Trading in the first six months of the current financial year has been in line with plan, with credit issued growth in Mexico home credit and IPF Digital and a modest contraction in European home credit. Portfolio quality remains within our target range and, as a result of stronger than expected post-field collections in our European home credit businesses, we now expect to exceed the current 2018 profit before tax consensus of £99.4m by approximately 10%.  Our expectation for financial performance in 2019 remains broadly in line with current consensus.”


Triple Point Social Housing REIT (LON:SOHO) 107p £262.9m

“The Board of Triple Point Social Housing REIT plc is pleased to announce that the Group has exchanged contracts on one supported housing property and completed the acquisition of two supported housing properties, and has also acquired the land and entered into a forward funding arrangement in respect of a further supported housing scheme. These commitments comprise 51 units in total, for an aggregate commitment of £6.7m (excluding costs). The properties are located in the North of England (39 units) and the East Midlands (12 units).”


Inspired Energy (LON:INSE) 19.8p £118.4m

Cornwall Insight, a leading independent consultancy to the UK energy market which provides research, insight and intelligence to market participants and their advisors, has just released its Q1 2018 update 'TPIs in the Business and Industrial energy Supply Markets'. Inspired Energy is ranked as the leading  TPI ('third party intermediary) in the Industrial & Commercial ("I&C") sector index rankings. 

Inspired is a provider of essential energy advisory services and intelligent energy solutions.


Providence Resources (PVR.L) 10.62p £63.5m

“The Irish based Oil and Gas Exploration Company, provides a Licence Update on Frontier Exploration Licence ("FEL") 2/14.

Providence is pleased to confirm that, having received approval from the Minister of State at the Department of Communications, Climate Action and Environment, the farm-out comprising the assignment of equity (35%) and transfer of operatorship of FEL 2/14 to TOTAL E&P Ireland B.V., a wholly owned subsidiary of TOTAL S.A., has now completed.  FEL 2/14 contains the undrilled Diablo prospect as well as the drilled Druid & Drombeg prospects.

The equity in FEL 2/14 is now TOTAL (Operator - 35%), Capricorn (30%), a wholly owned subsidiary of Cairn Energy PLC, Providence Resources P.l.c. (28%) and Sosina Exploration Limited (7%). “


DP Eurasia (LON:DPEU) 178p £257.6m

FYJun18 update from the exclusive master franchisee of the Domino's Pizza brand in Turkey, Russia, Azerbaijan and Georgia . Continued top line growth and strong digital engagement.

The Board expects the full year Adjusted EBITDA for 2018 to be in line with expectations

79 new stores were added over the last 12 months, bringing the total number to 672

Group system sales growth of 28.1% driven by strong growth in both Russia and Turkey

Turkish systems sales growth of 15.6%

Russian system sales growth of 68.8% (54.0% based on RUB)


RhythmOne (LON:RTHM) 182p £136.4m

RhythmOne's Q12019 financial performance was in line with management expectations. The Company started the year strong with quarter-over-quarter growth in both revenue and EBITDA. This upward trajectory was fuelled by continued growth in programmatic platform revenues. The Company is tracking against its key objectives for the year:

Enhancing its unified programmatic advertising platform;

Growing its base of data-driven engaged audience segments; and

Innovating around video and connected TV (CTV) advertising. "The RhythmMax platform continues to drive growth as we add additional controlled supply, package premium inventory for sale within private marketplaces and advance our leadership position within CTV. These steps underscore our overall strategic focus on mobile, video and programmatic trading - which we intend to maintain throughout FY2019.” 


James Latham (LON:LTHM) 670p £133m

“James Latham announces that Chris Sutton, an Executive Director of the Company, has informed the Board of his intention to retire on 31 March 2019.  Chris is Managing Director of Lathams Limited, the Group's trading subsidiary, and has served on the plc board since 2005.

Executive Director Andrew Wright will be appointed Managing Director of Lathams with effect from April 2019. Andrew has worked for the Company for 17 years and has been on the plc board since 2015.  He is currently the director responsible for panels and is an integral part of the senior management team.”


Creo Medical Group (LON:CREO) 137p £104m

The medical device company focused on the emerging field of surgical endoscopy, announces that it has conditionally raised, in aggregate, up to £48.5m at 125p. Proceeds will enable Creo amongst other thing:

to extend the Company's Clinical Education Program both by the Company and in conjunction with select distribution partners globally;

increase the number of distribution agreements with third parties and partners worldwide;

accelerate the roll out of its products;

extend the Company's existing manufacturing capability to support the extension of the Clinical Education Program and product roll out;

increase product line / range;

accelerate US roll out by seeking to establish a presence in the United States;


Genedrive (LON:GDR) 29.5p £5.4m

genedrive, the near patient molecular diagnostics company, provided an unaudited trading update for the twelve months ended 30 June 2018.

Diagnostic related revenue (Genedrive®) was £1.9m (2017: £2.6m). The Company closed the period with cash of £3.5m (31 Dec 2017: £4.6m) reflecting in part the completion of the Services Business disposal in June 2018. The revenue reduction versus the previous year was anticipated, and in line with market expectations, reflecting the successful completion of the US Department of Defence development contract. Diagnostics is now the Company's only reporting segment following the disposal of Services.

genedrive made its first commercial shipments of the Genedrive HCV® ID Kit in February 2018 and following these initial shipments, further commercial sales have followed. The Company is currently progressing registration and import licenses in approximately 30 countries. In conjunction with our distributors, we took the decision to hold back product registrations so we could include new extended product stability claims. These improved performance claims will assist future commercialisation efforts and we envisage the majority of registration dossiers being submitted during the next month.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use